Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to HER2-positive Breast Cancer
Related studies linked through entity extraction aliases.
Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy
- Status
- UNKNOWN
- Phase
- N/A
Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
ATEMPT 2.0: Adjuvant T-DM1 vs TH
- Status
- RECRUITING
- Phase
- PHASE2
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Tucatinib Together With Pembrolizumab and Trastuzumab
- Status
- TERMINATED
- Phase
- PHASE2
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
- Status
- UNKNOWN
- Phase
- PHASE2
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
- Status
- COMPLETED
- Phase
- N/A
De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade
- Status
- TERMINATED
- Phase
- PHASE2
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
- Status
- SUSPENDED
- Phase
- PHASE1
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis
- Status
- UNKNOWN
- Phase
- PHASE2
Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
- Status
- UNKNOWN
- Phase
- N/A
Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1